Lantheus Holdings, Inc. · NASDAQ:LNTH

Lantheus — Merger or Acquisition (January 2025)

11 slides from Lantheus's merger presentation, Jan 13, 2025

  1. Slide 1: Lantheus to Acquire Life Molecular Imaging

    Lantheus to Acquire Life Molecular Imaging Accelerating Innovation for Patients in the Growing Alzheimer’s Disease Radiodiagnostic Market January 13, 2025 © 2025 Lantheus. All rights reserved. 1

  2. Slide 2: Agenda

    Acquisition Overview & Strategic Rationale Transaction Summary Commercial Infrastructure and R&D Capabilities Agenda Growth Strategy Q&A © 2025 Lantheus. All rights reserved.

  3. Slide 3: Safe Harbor Statements

    Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties and are made pursuant to the safe harbor provision

  4. Slide 4: Acquisition of Life Molecular Imaging (LMI) Delivers Compelling Strategic, Operational, and Financial Benefits

    Acquisition of Life Molecular Imaging (LMI) Delivers Compelling Strategic, Operational, and Financial Benefits Establishes commercial Expands growth profile Enhances R&D and clinical Strengthens innovative franchise in growing with Neuraceq®, a capabilities to accelerate radiodiagnostic pipeline Alz

  5. Slide 5: Life Molecular Imaging: Established Radiopharmaceutical Player

    Life Molecular Imaging: Established Radiopharmaceutical Player International, commercial-stage radiopharmaceutical company, with globally-approved product (Neuraceq), commercial infrastructure, A Global Brand1 and promising pipeline/R&D expertise Favorable relationships with manufacturers, hospitals

  6. Slide 6: Transaction Summary

    Transaction Summary Overview Compelling Financial Rationale Acquiring Life Molecular Imaging from Life Healthcare (LHC.JO) Anticipated to drive an increase in consolidated, organic annual revenue growth by approximately ALL CASH, DEBT-FREE TRANSACTION 200 to 300 basis points over the next three year

  7. Slide 7: ESTABLISHES Commercial Franchise

    ESTABLISHES Commercial Franchise Operational and commercial expertise POSITIONED TO EXPAND Neuraceq access to Existing and complementary millions of Alzheimer’s AD capabilities patients around the world New Late-Stage Pipeline Programs Potential to provide precise, real-time 18F-PI-2620 LMI’s radiod

  8. Slide 8: Remarkable Market Growth in Alzheimer's Diagnostics

    Remarkable Market Growth in Alzheimer's Diagnostics National Institute on Aging Alzheimer’s Association SNMMI Market Potential U.S. AD PET radiodiagnostics TAM $2.5 RECOMMEND $1.5 Amyloid- and tau-PET imaging USD Billions3 for diagnosis, staging, & treatment monitoring1, 2 2030 mid-2030 LMI Acquisit

  9. Slide 9: Transaction Supports Strategy and Long-Term Value Creation

    Transaction Supports Strategy and Long-Term Value Creation Aligns with Lantheus’ strategy to enhance our radiopharmaceutical leadership by expanding our capabilities, diversifying our business, and strengthening our long- term growth potential through inorganic actions Enhances Adds Significant U.S.

  10. Slide 10: Appendix

    Appendix © 2025 Lantheus. All rights reserved. 10

  11. Slide 11: Enhances Growth Profile with Approved Alzheimer's Disease Radiodiagnostic

    Enhances Growth Profile with Approved Alzheimer’s Disease Radiodiagnostic 18F-florbetaben is a selective, reversible, high-affinity binding amyloid-beta PET agent1 • Indicated for PET imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who a

Lantheus Holdings — Merger or Acquisition (January 2025) on 6ix